New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
04:55 EDTBOTA, BOTA, BOTA, BOTA, IMGN, IMGN, IMGN, IMGN, ARRY, ARRY, ARRY, ARRY, OFIX, OFIX, OFIX, OFIX, CMN, CMN, CMN, CMN, MDCO, MDCO, MDCO, MDCO, TTHI, TTHI, TTHI, TTHI, INO, INO, INO, INO, CNAT, CNAT, CNAT, CNAT, Q, Q, Q, QJefferies to hold a conference
2014 Global Healthcare Conference to be held in New York on June 2-5.
News For BOTA;CNAT;INO;TTHI;MDCO;CMN;OFIX;ARRY;IMGN;Q From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
February 1, 2016
12:13 EDTIMGNOn The Fly: Top stock stories at midday
Stocks on Wall Street were lower at midday, but off their worst levels of the day, as oil is once again being weighed on by worries of slower growth in China. Several M&A announcements helped fuel speculation that deal-making may be set to pick up, but the headwinds of lower oil prices and weak economic data are outweighing that potential boost and keeping stocks in the red to start the month. ECONOMIC EVENTS: In the U.S., personal income rose 0.3% in December, versus expectations for an increase of 0.2%, while spending was flat, versus expectations for an increase of 0.1%. Markit's manufacturing purchasing managers index for January dipped to 52.4 in the final January reading, down from the 52.7 flash reading and the below the 52.6 reading that was expected. The Institute for Supply Management's manufacturing index for January came in at 48.2, below the 48.4 that analysts expected. Construction spending rose 0.1% in December, which was weaker than the 0.6% increase that was forecast. In China, the statistics bureau's official manufacturing purchasing managers index fell to 49.4 in January from 49.7 in December. The private Caixin manufacturing PMI edged up to 48.4 from 48.2 in the prior reading, but both figures still remain in contraction territory. In Europe, Markit's manufacturing PMI for the euro zone dropped to 52.3 from December's 53.2, in-line with the earlier flash estimate. COMPANY NEWS: Shares of Twitter (TWTR) advanced 9% after tech reporter Jessica Lessin said private equity firm Silver Lake and investor Marc Andreessen have "considered some sort of deal" for the microblog service operator. Lessin noted in the report published on her site, The Information, that she did not know if deal talks are "active" now between Andreessen, Silver Lake and Twitter... Alere (ALR) surged 45% to $54 per share near midday after Abbott (ABT) agreed to acquire the company for $56 per share at a total expected equity value of $5.8B. In other Monday M&A news, Questar (STR) rose 22% after Dominion Resources (D) agreed to acquire it for $25 per share, or about $4.4B, and assume Questar's outstanding debt. Meanwhile, Stryker (SYK) announced a deal to acquire Sage Products for $2.775B in cash. The buyers' shares did not fare as well in the wake of the deal announcements, as Abbott slipped 0.5%, Dominion dipped 1% and Stryker fell 1%. Also lower were shares of Smith & Nephew (SNN), which slid fractionally as investors may have been concerned that Stryker's deal decreases the likelihood that it will come after S&N. Additionally, Smith & Nephew announced that its CEO Olivier Bohuon has been diagnosed with a "highly treatable" form of cancer. MAJOR MOVERS: Among the notable gainers was Lumber Liquidators (LL), which gained 8.5% after a judge accepted the company's $10M plea deal to settle timber source crime charges, according to media reports. Also higher was Chipotle (CMG), which rose 5.5% after The Wall Street Journal reported that the Centers for Disease Control and Prevention is expected to formally declare the end to its E.coli outbreak as soon as today. In addition, Sysco (SYY) and Aetna (AET) were up 7% and 2%, respectively, after reporting quarterly earnings. Among the noteworthy losers was Nokia (NOK), which fell 12% after it forecasted how much revenue it expects to gain from its IP portfolio after its patent deal with Samsung (SSNLF) and its shares were downgraded at Canaccord and BofA Merrill Lynch. Also lower was GoPro (GPRO), which was slid 5% after analysts from Piper Jaffray and Citi predicted that the company's guidance to be issued this week will disappoint investors. In addition, Roper Technologies (ROP) and ImmunoGen (IMGN) were down 6.5% and 5.7%, respectively, after reporting quarterly earnings. INDEXES: Near midday, the Dow was down 56.40, or 0.34%, to 16,409.90, the Nasdaq was down 12.25, or 0.27%, to 4,601.70, and the S&P 500 was down 6.51, or 0.34%, to 1,933.73.
11:57 EDTARRYDana-Farber, Array BioPharma to collaborate on immuno-oncology research
Dana-Farber Cancer Institute announced announced an immuno-oncology collaboration with potential applicability in a wide range of oncology indications with Array BioPharma. The research team at Dana-Farber's Robert and Renee Belfer Center for Applied Cancer Science will work with Array scientists on novel immune-oncology targets with the goal of bringing innovative medicines to patients. The collaboration will leverage the Belfer Center's proprietary immuno-oncology platform. Combining Dana Farber's oncology expertise with the Array's proficiency in drug discovery provides a unique opportunity to accelerate drug discovery of effective medicines for patients with unmet medical need.
08:51 EDTMDCOThe Medicines Co. completes divestiture of hemostasis portfolio to Mallinckrodt
Subscribe for More Information
06:18 EDTTTHITransition Therapeutics announces results from Phase 2 clinical study of TT401
Subscribe for More Information
06:11 EDTTTHITransition Therapeutics reports results from Phase 2 clinical study of TT401
Subscribe for More Information
05:57 EDTINOInovio volatility elevated, developing vaccine for Zika virus infection
Inovio February call option implied volatility is at 108, March is at 100; compared to its 52-week range of 49 to 115, suggesting large price movement as the company develops a DNA-based vaccine for preventing and treating the Zika virus infection.
January 29, 2016
13:19 EDTINOOptions with increasing call volume: EXP FLIR SYN INO PBR VMEM EPI GILD EA
Subscribe for More Information
10:03 EDTINOHigh option volume stocks: GIMO CSOD NAVI ALGN IMPV LC INO FMC VMW RCII
Subscribe for More Information
09:21 EDTINOOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Gigamon (GIMO), up 17.7%... Fortinet (FTNT), up 10%... Flextronics (FLEX), up 10%... Skyworks (SWKS), up 5.7%... Seagate Technology (STX), up 4.9%.. Microsoft (MSFT), up 4.6%. ALSO HIGHER: Inovio Pharmaceuticals (INO), up 8.1% after CEO says Zika vaccine could enter human testing this year... J.C. Penney (JCP), up 2.1% after being upgraded to Neutral from Underperform at Credit Suisse... BRF S.A. (BRFS), up 3.1% after being upgraded to Buy from Hold at Deutsche Bank... Axiall (AXLL), up 83.4% after rejecting $20 per share acquisition proposal from Westlake Chemical (WLK)... Energous (WATT), up 12% after Bloomberg reported that Apple (AAPL) is working with partners in the U.S. and Asia to develop new wireless charging technology. DOWN AFTER EARNINGS: Amazon.com (AMZN), down 10.1%... Electronic Arts (EA), down 6.2%... AbbVie (ABBV), down 4%... American Airlines (AAL), down 1.3%. ALSO LOWER: Gilead Sciences (GILD), down 5.5% after CEO John Martin to assume role of executive chairman and COO John Milligan will be promoted to CEO.
08:52 EDTINOInovio rises as CEO says Zika vaccine could enter human testing this year
Inovio Pharmaceuticals (INO) shares are rising again this morning as the Zika virus continues to gain attention and its CEO says the company is "ahead of the pack" in developing a vaccine to combat the disease. YEAR END TESTING POSSIBLE: Joseph Kim, CEO of Inovio, said making a vaccine available by the end of this year is aggressive, but possible, according to Reuters, which quoted Kim as saying, "I believe this will be the first to go into human testing. We believe we're ahead of the pack in the race for a Zika vaccine." WHAT'S NOTABLE: The head of the World Health Organization, Dr. Margaret Chan, said the Zika virus, which has been linked to neurological ailments, especially in fetuses and newborns, is "now spreading explosively" in the Americas. WHO now predicts that Zika could infect as many as 4M people in the Americas. ANOTHER TO WATCH: Cerus (CERS) is also at work on combating Zika. A study, partially funded by Cerus, showed that amotosalen combined with UVA light inactivates Zika virus in fresh-frozen plasma, according to an earlier report. PRICE ACTION: Inovio shares, which gained over 7.5% yesterday, are up another 9% to $6.30 in pre-market trading.
06:32 EDTIMGNImmunoGen backs FY16 revenue $70M-$80M, consensus $75.14M
Subscribe for More Information
06:31 EDTIMGNImmunoGen reports Q2 EPS (38c), consensus (36c)
Subscribe for More Information
January 28, 2016
16:40 EDTINOOn The Fly: Top stock stories for Thursday
The Dow began the session with triple digit gains thanks in part to solid earnings reports from some of America's bellwether corporations and oil prices, which approached $34 a barrel. The market was unable to hold its opening gains and eventually crossed into negative territory. Before the losses became too big the averages reversed and moved back across the flat line. With oil holding onto its gains and closing above $33 a barrel, the averages closed in positive territory ahead of the next barrage of earnings reports. ECONOMIC EVENTS: In the U.S., initial jobless claims fell to 278,000 last week, versus the expected 281,000 first-time claims. Durable goods orders dropped 5.1% in December, versus expectations for a decrease of 0.7%. The core reading, which removes transportation items, was down 1.2%, versus expectations for a decline of 0.1%. The National Association of Realtors' pending home sales index for December rose 0.1%, versus expectations for it to be up 0.9%. COMPANY NEWS: Shares of Facebook (FB) surged 15.5% to $109.11 after the social media giant's fourth quarter earnings and revenue beat expectations. A number of Wall Street analysts increased their price targets for the stock following the report, including Piper Jaffray's Gene Munster, who hiked his target to a "Street-high" $170 per share. Facebook management made only one mention of macro concerns for the business in 2016, significantly different than Apple's (AAPL) earnings call on Tuesday night, Munster pointed out... Caterpillar (CAT) reported better than expected quarterly earnings, excluding certain items, but its revenue came in below the consensus forecast and the heavy equipment maker warned that it does not anticipate an improvement in the world economy or commodity prices in 2016. The stock, which had declined almost 20% in the last three months prior to this morning's report, rebounded 4.7% to $61.08 after the company jumped over the lowered bar that had been set by bearish analysts... Under Armour (UA), which had similarly been the focus of concern recently for some bearish analysts, posted better than expected results on the top and bottom line and backed its fiscal year revenue forecast, proving its doubters wrong and sending its share rocketing up 22.5% to $84.00. MAJOR MOVERS: Among the notable gainers were Intrexon (XON), Inovio (INO) and Cerus (CERS), which gained a respective 10%, 7.6% and 1.4% as the ongoing Zika virus scare brought attention to the companies' efforts fighting the illness. Also higher were SolarCity (SCTY), Sunrun (RUN) and Vivint Solar (VSLR), with the solar stocks jumping 8.5%, 20.5% and 3.6%, respectively, after the California Public Utilities Commission approved new net-metering rules. Meanwhile, Eagle Pharmaceuticals (EGRX) rose 12.2% to $74.44 after announcing commercial availability of its Bendeka injection in partnership with Teva (TEVA). Among the noteworthy losers was Yahoo (YHOO), which lost 3.2% to $28.75 despite a pre-market spike after SpringOwl Asset Management urged the company to seek an investment from a strategic partner. The news was also followed by reports that CEO Marissa Mayer has started restructuring efforts with an "invest/maintain/kill" list, as well as news that Verizon (VZ) denied a report that it had bid for the company's core Internet business. Also lower were OSI Systems (OSIS), Qualcomm (QCOM) and eBay (EBAY), which fell a respective 31.8%, 8.3% and 12.5% following their quarterly earnings reports. INDEXES: The Dow rose 125.18, or 0.79%, to 16,069.64, the Nasdaq gained 38.51, or 0.86%, to 4,506.68, and the S&P 500 advanced 10.41, or 0.55%, to 1,893.36.
14:29 EDTIMGNNotable companies reporting before tomorrow's open
Subscribe for More Information
12:49 EDTINOCerus spikes as journal discusses treatment of Zika virus
Shares of Cerus (CERS) are rallying after a Transfusion journal article posted on Read Cube made its way through the investment community. The article describes a study, partially funded by Cerus, which showed that amotosalen combined with UVA light inactivates Zika virus in fresh-frozen plasma. Shares of Inovio (INO) are also higher today as news agencies report on more Zika virus cases. Cerus is up 36c to $5.55 in afternoon trading. Reference Link
07:16 EDTINOInovio, GeneOne initiate patient recruitment for MERS vaccine trial
Inovio Pharmaceuticals announced the beginning of recruitment for its collaborative vaccine study for MERS. Inovio and GeneOne Life Science Inc. are co-developing Inovio's MERS vaccine in partnership with the Walter Reed Army Institute of Research in Maryland, where the trial is being conducted. The primary and secondary goals of this first-in-man phase I trial are to obtain safety and immunogenicity data. This trial represents the first MERS vaccine to be tested in humans for this disease that has no approved vaccines or treatments.
January 26, 2016
06:33 EDTIMGNImmunoGen earns milestone payment from Bayer related to BAY 94-9343
Subscribe for More Information
January 22, 2016
09:55 EDTINOInovio mentioned positively at Maxim
Subscribe for More Information
09:39 EDTMDCOThe Medicines Co. takeout price could be $69/share, says Jefferies
Jefferies analyst Biren Amin believes The Medicines Co.'s (MDCO) acquisition price could be around $69 per share prior to the Phase 2 ORION-1 data results. The analyst says he's received inquiries from investors regarding a potential takeout price following Bloomberg's report that the company has hired advisers to explore a sale. Amin used the recent Dyax (DYAX) acquisition as a comparable proxy. If Medicines were to wait until after the Phase 2 data, it could be acquired for $99 per share should the study results be positive, Amin tells investors in a research note. He keeps a Buy rating on The Medicines Co. with a $50 price target.
05:29 EDTINOGeneOne Life Science and Inovio to collaborate on Zika Virus vaccine
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use